Abbott reports Exact Sciences integration, ending Exact Sciences stock trading

Published on 10/01/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences stock became an Abbott subsidiary on March 23, 2026. The merger paid USD 105.00 per share and ended Nasdaq trading.

Schwarz-Weiß-Reportage einer Pathologin am Mikroskop im Diagnostiklabor von Exact Sciences — Exact Sciences Corp. zeigt den diagnostischen Laboralltag in einer eindrucksvollen Schwarzweiß Reportagefotografie US30063P1057, Illustration mit AI erstellt.

Abbott reports that it completed the acquisition of Exact Sciences on March 23, 2026, making the cancer diagnostics company a wholly owned subsidiary and ending independent Exact Sciences stock trading. According to StockTitan, each Exact Sciences share converted into USD 105.00 in cash at closing.

Abbott takes over cancer diagnostics

The transaction created Abbott's Cancer Diagnostics business around Cologuard, Oncotype DX and Cancerguard. The structure moved Exact Sciences from a standalone public company into Abbott's broader diagnostics operation.

Exact Sciences describes its portfolio as covering cancer screening, hereditary-risk testing and genomic analysis used to guide treatment. That combination gives Abbott exposure to both population screening and precision oncology.

Historical revenue showed scale

Before the acquisition, Exact Sciences reported USD 878.4 million of revenue in the fourth quarter of 2025, according to GetSignal.

That figure was up 23.13 percent from USD 713.4 million in the fourth quarter of 2024. The same historical comparison also showed a diluted loss of USD 0.45 per share in the fourth quarter of 2025, highlighting the gap between revenue expansion and profitability before the deal closed.

The public listing has ended

StockTitan identifies March 20, 2026 as Exact Sciences' last trading day on Nasdaq and March 23, 2026 as the acquisition closing date. The former EXAS security therefore belongs to the company's historical market record rather than an active standalone listing.

MarketScreener identifies the former security as Exact Sciences Corporation under ticker EXAS and ISIN US30063P1057. The acquisition price provides the clearest final equity reference: USD 105.00 per share in cash, rather than an ongoing exchange quotation.

Ownership now defines the equity story

For investors reviewing the former stock, the central change is structural. Exact Sciences' screening and oncology products remain operational, but capital allocation and future reporting now sit within Abbott's corporate framework.

The further course of trading is shown by the continuously updated real-time quote of Exact Sciences stock.